Acute Cognition and Exercise

Overview

The central hypothesis is that, while both groups will benefit from the exercise session, participants with obesity will exhibit greater gains in cognitive control, relative to healthy weight adults. Additionally, it is anticipated that the benefits of a single bout of exercise for cognitive control will be mediated by changes in exercise-induced myokines. These hypotheses will be tested by accomplishing three aims: Aim 1: Elucidate the changes in cognitive control following an acute bout of exercise, relative to a sedentary condition, in persons with and without obesity. Aim 2: To examine the effect of a single bout of exercise, relative to a sedentary condition, on myokines known to have neuroprotective effects i.e., BDNF and CTSB in both healthy weight and individuals with obesity. Aim 3: To link changes in exercise-induced myokines (i.e., BDNF and CTSB) to changes in cognitive function, following a single bout of exercise.

Full Title of Study: “Acute Exercise and Cognitive Function: Examining the Role of Weight Status and Exercise-Induced Myokines”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Prevention
    • Masking: None (Open Label)
  • Study Primary Completion Date: April 28, 2022

Detailed Description

18 adults with healthy weight (BMI 18.5-25.0kg/m2) and 18 adults with obesity (BMI 30.0kg/m2) will be asked to complete a counter-balanced crossover trial. After initial baseline testing, participants will be asked to complete either an acute exercise bout or sedentary control session in a counter-balanced order. A cognitive testing battery accompanied by an electroencephalogram (EEG) will be administered following each session. Blood samples will be collected prior to, during, and following each throughout each testing condition.

Interventions

  • Behavioral: Exercise
    • 36 minutes of Exercise

Arms, Groups and Cohorts

  • Experimental: Exercise
    • 36 minutes of exercise
  • Placebo Comparator: Rest
    • 36 minutes of rest

Clinical Trial Outcome Measures

Primary Measures

  • Circulating Cathepsin B (CTSB) Myokine
    • Time Frame: 3 hours
    • Changes in peripheral myokine concentration
  • Attentional Inhibition Accuracy
    • Time Frame: 3 hours
    • Behavioral performance measured as accuracy (%) during Flanker task
  • Attentional Inhibition Reaction Time
    • Time Frame: 3 hours
    • Behavioral performance measured as response time (ms) during Flanker task
  • Attentional Resource Allocation
    • Time Frame: 3 hours
    • Changes in P3 event related potential amplitude (microvolts) using a computerized flanker task
  • Attentional Processing Speed
    • Time Frame: 3 hours
    • Changes in P3 event related potential latency (ms) using a computerized flanker task
  • Relational Memory
    • Time Frame: 3 hours
    • Accuracy during a spatial reconstruction task

Secondary Measures

  • Brain derived neurotrophic factor (BDNF)
    • Time Frame: 3 hours
    • Changes in peripheral BDNF concentration

Participating in This Clinical Trial

Inclusion Criteria

  • Between ages 18 and 35 – No prior diagnosis of neurological disorders (e.g., autism spectrum disorder) – No prior diagnosis of metabolic disease (e.g., diabetes, cardiovascular disease) – No physical disability that would preclude the participant from completing a VO2max test – Corrected vision (based on the minimal 20/20 standard needed to complete cognitive tasks) – Not pregnant – BMI between 18.5 and 25.0 kg/m2, or BMI greater than 30.0 kg/m2 – Readiness for exercise (determined through PAR-Q) Exclusion Criteria:

  • <18 years and >35 years – Diagnosis of neurological disorders (e.g., autism spectrum disorder) – Diagnosis of metabolic disease (e.g., diabetes, cardiovascular disease) – Physical disability that would preclude the participant from completing a VO2max test – Lack of corrected vision (based on the minimal 20/20 standard needed to complete cognitive tasks) – Pregnancy – BMI less than 18.5 kg/m2 or BMI greater than 25.0 but less than 30.0 kg/m2

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 35 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • University of Illinois at Urbana-Champaign
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.